Vafidemstat

Vafidemstat is a dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor.

Signaling Pathways >> Epigenetics >> Histone Demethylase

Signaling Pathways >> Neuronal Signaling >> Monoamine Oxidase

Research Areas >> Neurological Disease

LSD1/MAO-B[1]

Vafidemstat (ORY-2001), a dual LSD1/MAO-B inhibitor, is a novel epigenetic agent for the treatment of neurodegenerative diseases. LSD1 is a protein that participates in transcription regulation complexes; its modulation can be used to tweak transcriptional imbalances in neurodegenerative disease and redress neuroinflammation and cognitive deficit[1]. Vafidemstat (ORY-2001) can be used in the treatment of Alzheimer's disease[2].

[1]. ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer’s and Parkinson’s diseases

[2]. ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2018.

GSK-J4 | QC6352 | GSK2879552 | SP-2509 | CPI-455 | Phenelzine (sulfate) | trans-2-Phenylcyclopropylamine hemisulfate salt | 5-Carboxy-8-hydroxyquinoline | Clorgyline hydrochloride | ML324 | Rosmarinic acid | pargyline hydrochloride | GSK-LSD1 Dihydrochloride | NCGC00244536 | Daminozide